University of Kentucky
Lexington, Kentucky, 40507, United States
Location status: Recruiting
NCT Number: NCT07188376
The goal of this clinical trial is to learn how a specific type of brain stimulation affects alcohol-related decision-making and self-control in adults who drink alcohol. The main questions the study aims to answer are:
* Does brain stimulation change how people behave after drinking alcohol? * Does the combination of alcohol and different types of brain stimulation affect people's ability to make thoughtful decisions or resist impulses?
Researchers will compare the effects of two types of brain stimulation, intermittent theta burst stimulation (iTBS) and continuous theta burst stimulation (cTBS), after people drink alcohol or a placebo drink. A sham (placebo) stimulation condition will also be included. The study uses a within-person design, which means each participant will take part in all conditions.
Participants will:
* Attend five separate study visits * Drink either an alcoholic or placebo beverage * Receive one of the brain stimulation conditions (real or sham) * Complete decision-making tasks before and after drinking
The tasks will measure things like impulsive choices and reaction time. The researchers hope this study will help identify how brain stimulation could be used to improve decision-making during intoxication, which might one day reduce harmful drinking behaviors or prevent alcohol-related accidents.
Interested in participating?
Request Info21 year–29 year
All sexes
Interventional
Not applicable
Lexington, Kentucky, 40507, United States
Location status: Recruiting
This study aims to understand how brain stimulation affects decision-making and behavioral control after alcohol consumption. Many harmful events related to alcohol use are the result of impaired decision-making while intoxicated. Although there are medications that reduce alcohol cravings, there are few tools available to reduce the negative behavioral effects of alcohol once someone has already consumed it.
This clinical trial uses non-invasive brain stimulation, known as transcranial magnetic stimulation (TMS), to target a brain area called the prefrontal cortex, which helps regulate decision-making and self-control. TMS can increase or decrease activity in targeted brain areas using magnetic pulses. Two specific types of stimulation will be tested:
Participants will be healthy adults who report regularly drinking alcohol. Each participant will attend five sessions in a randomized, within-subject design. Across the sessions, participants will experience each of the following conditions:
Each session will be conducted on a separate day and will include:
The behavioral Go/No-Go Task will measure:
The study's goals are to:
The stimulation dose and session timing are designed to align with the typical rise and fall of blood alcohol levels. Each stimulation session will use a "ramping" protocol to gradually increase stimulation intensity, improving tolerability. Safety and tolerability will be carefully monitored.
This study builds on previous work showing that TMS can influence decision-making but is the first to examine whether TMS can be used during alcohol intoxication to improve behavioral control. If successful, the findings may lead to new interventions for preventing risky or harmful behaviors associated with alcohol use.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Intermittent Theta Burst Stimulation (iTBS) is then delivered to the left DLPFC using a MagVenture TMS device. Each iTBS session includes 600 pulses delivered in 3-pulse bursts at 50 Hz, every 200 ms (5 Hz), in 2 sec on / 8 sec off cycles at 110% resting motor threshold (RMT). Stimulation is ramp-up from 80% to 110% RMT (~90 pulses). Two iTBS sessions are given per visit, separated by 30 minutes. The second session is timed to correspond to the peak BAC.
Continuous Theta Burst Stimulation (cTBS) is then delivered to the left DLPFC using a MagVenture TMS device. Each cTBS session includes 2 bouts of 1800 pulses separated by a 1 minute rest period. Each bout is delivered in 3-pulse bursts at 50 Hz, every 200 ms (5 Hz), continuously for ~120 seconds at 110% resting motor threshold (RMT). Stimulation is ramped up from 80% to 110% RMT over the first 30 seconds. Two cTBS sessions are given per visit, separated by 30 minutes. The second session is timed to correspond to the peak BAC.
Sham Transcranial Magnetic Stimulation (TMS) is delivered to the left DLPFC using the sham side of a MagVenture TMS coil, paired with synchronized scalp electrodes to mimic the sensation of real TMS. The sham procedure matches the timing and auditory cues of either iTBS or cTBS protocols, depending on random assignment. Two sham stimulation sessions are given per visit, separated by 30 minutes. The second session is timed to correspond to the peak BAC.
Time frame: Measured at baseline, immediately after the second TMS session at peak BAC (~0.08%), and again on the descending limb of BAC (~0.05%) (approximately 3 hours total)
Change in the proportion of inhibition failures (p-failures) on the cued Go/NoGo task from baseline to post-intervention under each experimental condition. Higher p-failure rates reflect poorer inhibitory control. This outcome will be measured following each TMS and alcohol condition (iTBS, cTBS, sham × active or placebo alcohol), and assessed across timepoints (peak Blood Alcohol Concentration (BAC) ~0.08% and descending BAC ~0.05%).
Time frame: Measured at baseline, at peak BAC, and on the descending limb of BAC (approximately 3 hours total)
Average response latency (in milliseconds) to correctly identified Go stimuli on the cued Go/NoGo task. This measure reflects psychomotor speed and processing efficiency and will be used to assess general effects of alcohol and/or TMS interventions.
Time frame: Assessed within-session at peak and descending BAC (approximately 3 hours total)
Exploratory analysis of behavioral changes (e.g., p-failures, Go reaction times) across different phases of the blood alcohol curve (peak ~0.08% vs. descending ~0.05%) under each intervention condition. This outcome will assess whether effects of TMS on inhibitory control and response latency are state-dependent relative to the intoxication curve.
Contact information is provided by the study sponsor or research team.
Mark T. Fillmore, Ph.D.
CONTACT
Michael J. Wesley, Ph.D.
CONTACT
Michael J. Wesley, PhD
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02584621
Alcohol Risk Behaviors, Health Care Services Quality of Care
Seattle, Washington, United States
View Trial DetailsNCT04725409
Anxiety Disorders, Behavior
Nashville, Tennessee, United States
View Trial DetailsNCT06921226
Behavior, Behavioral Symptoms
Chambéry, Savoie, France
View Trial DetailsNCT03457402
Behavior, Impulsive Behavior
Sacramento, California, United States
View Trial Details